Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

BACKGROUND/AIMS: Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Young Eun, Suh, Sang Jun, Yim, Hyung Joon, Seo, Yeon Seok, Yoon, Eileen L., Kim, Tae Hyung, Lee, Young Sun, Yim, Sun Young, Kim, Hae Rim, Kang, Seong Hee, Jung, Young Kul, Kim, Ji Hoon, Yeon, Jong Eun, Um, Soon Ho, Byun, Kwan Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960975/
https://www.ncbi.nlm.nih.gov/pubmed/32307975
http://dx.doi.org/10.5009/gnl19367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960975/
https://www.ncbi.nlm.nih.gov/pubmed/32307975
http://dx.doi.org/10.5009/gnl19367

Ejemplares similares